Enlivex Therapeutics Ltd
NASDAQ:ENLV
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Price:
1.08
USD
3.85%
Market Cap:
$256.4m
Relative Value
There is not enough data to reliably calculate the relative value of ENLV.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ENLV
Relative Value
Base Case
Not Available
Multiples Across Competitors
ENLV Competitors Multiples
Enlivex Therapeutics Ltd Competitors
Enlivex Therapeutics Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IL |
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
256.4m USD | 0 | -20.2 | -16.6 | -16.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
393.8B USD | 6.4 | 94.1 | 15.5 | 21.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.4B USD | 5.3 | 25.2 | 14.6 | 14.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.2B USD | 6.1 | 21.1 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD | 9.8 | 29.8 | 22.5 | 23.5 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.1B USD | 5.6 | 17.8 | 13.3 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68.1B AUD | 3.1 | 34.6 | 11.4 | 14.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.8B EUR | 10.8 | 34.6 | 37.5 | 38.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
